Role of CDKN1C in hypopharyngeal cancer

2020 Fiscal Year Final Research Report

• Project/Area Number: 17K11414
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: Imai Takayuki 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (80408583)
• Co-Investigator(Kenkyū-buntansha): 望月 麻衣 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 研究員 (40726303)
• Project Period (FY): 2017-04-01 – 2021-03-31
• Keywords: 頭頸部がん

Outline of Final Research Achievements

Head and neck cancer is a common cancer worldwide and its incidense is slowly increasing in Japan. Previously we investigated the CD271-CDKN1C pathway in hypopharyngeal cancer, and in this study we newly established an anti-CD271 antibody for treatment. The antibody exerts ADCC activity and shows a tumor-reducing effect in vivo. These results demonstrate the feasibility of antibody treatiment targeting CD271.

Free Research Field

腫瘍学

Academic Significance and Societal Importance of the Research Achievements

私たちは頭頸部がんの新規治療法確立のために、がん幹細胞マーカーであるCD271に対する抗体を作成し、治療できるか検討した。その結果、担癌マウスにおいて抗体投与群では腫瘍縮小効果を得られた。今後はさらに改善を行い、実用化を目指す。